- Home
- INMB vs IMMX Comparison
INMB vs IMMX Comparison
Compare INMB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- IMMX
- Stock Information
- Founded
- INMB 2015
- IMMX 2014
- Country
- INMB United States
- IMMX United States
- Employees
- INMB N/A
- IMMX N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- INMB Health Care
- IMMX Health Care
- Exchange
- INMB Nasdaq
- IMMX Nasdaq
- Market Cap
- INMB 68.9M
- IMMX 65.5M
- IPO Year
- INMB 2019
- IMMX 2021
- Fundamental
- Price
- INMB $1.89
- IMMX $2.18
- Analyst Decision
- INMB Buy
- IMMX Strong Buy
- Analyst Count
- INMB 4
- IMMX 1
- Target Price
- INMB $9.53
- IMMX $7.00
- AVG Volume (30 Days)
- INMB 806.4K
- IMMX 197.9K
- Earning Date
- INMB 10-30-2025
- IMMX 08-08-2025
- Dividend Yield
- INMB N/A
- IMMX N/A
- EPS Growth
- INMB N/A
- IMMX N/A
- EPS
- INMB N/A
- IMMX N/A
- Revenue
- INMB $50,000.00
- IMMX N/A
- Revenue This Year
- INMB $142.83
- IMMX N/A
- Revenue Next Year
- INMB $14,780.90
- IMMX N/A
- P/E Ratio
- INMB N/A
- IMMX N/A
- Revenue Growth
- INMB N/A
- IMMX N/A
- 52 Week Low
- INMB $1.86
- IMMX $1.26
- 52 Week High
- INMB $11.64
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- INMB 31.89
- IMMX 44.66
- Support Level
- INMB $1.86
- IMMX $2.16
- Resistance Level
- INMB $2.00
- IMMX $2.29
- Average True Range (ATR)
- INMB 0.13
- IMMX 0.16
- MACD
- INMB 0.01
- IMMX 0.01
- Stochastic Oscillator
- INMB 7.41
- IMMX 51.16
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.